Generally, compared with Non-NAFLD MAFLD participants, the Non-MAFLD NAFLD participants have better obesity status (BMI, waist circumference, overweight/obesity, central obesity), glucose metabolism (FPG, insulin, HbA1c, HOMA-IR, diabetes), lipid metabolism (TG, TC, HDL-C, LDL-C, dyslipidemia), blood pressure (systolic blood pressure, hypertension), liver function and steatosis (ALT, AST, hepatic steatosis), cardiovascular burden (Framingham risk score, previous CVD) and eGFR (P<0.05 for both male and female). This evidence concerns the gene INS and Hepatic steatosis.